Br J Cancer:三级淋巴样结构评分:改善非小细胞肺癌TNM分期的潜在预后预测方法

2021-03-20 xiaozeng MedSci原创

TNM分期系统可用于指导非小细胞肺癌(NSCLC)患者的治疗效果并评估其生存率。

TNM分期系统可用于指导非小细胞肺癌(NSCLC)患者的治疗效果并评估其生存率。随着研究的深入,越来越多的证据显示,免疫系统在癌症中起着至关重要的作用,再加上免疫疗法的出现,患者的原位免疫环境提供了重要的预后和预测信息。

该研究前期提出了一种免疫细胞评分(TNM-免疫细胞评分)分类系统,作为对NSCLC现有TNM分期系统的补充。在该研究中,研究人员主要探究了如何可靠地评估三级淋巴样结构(TLS)评分以完善TNM分期系统。

研究人员采用免疫组化(CD8/角蛋白)实验,通过在两个独立的集合中(共553名患者)使用三种不同的评分模型,对NSCLC患者切除的全肿瘤组织切片中的TLS进行了定量。并通过NanoString数字基因定量技术分析相关表达与TLS的关联性。

三级淋巴结构(TLS)在非小细胞肺癌组织中的分布

结果显示,相比于II期患者,III期患者的TLS数量显著减少。无论是采用何种(半)量化策略或分析相关研究终点(疾病特异性生存率、疾病生存率、总生存期、复发时间),均证实了TLS评分是一种独立的阳性预后因素。

免疫基因特征与三级淋巴结构(TLS)的关系

亚组分析结果显示,TLS评分在每个病理阶段、患者队列以及主要组织学亚型内均对患者的预后产生重大影响。靶向基因表达分析表明,高TLS水平与B细胞以及包括肿瘤炎症特征在内的适应性免疫基因相关。


综上,该研究结果揭示,TLS评分可以提高每个病理阶段患者的预后分析,其或可改善已进行手术切除的NSCLC患者的TNM分期。


原始出处:

Rakaee, M., Kilvaer, T.K., Jamaly, S. et al. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. Br J Cancer (15 March 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1689579, encodeId=b05f16895e9cd, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu Sep 16 14:31:39 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059966, encodeId=af10205996664, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 16 22:31:39 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952228, encodeId=e62b19522288c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Nov 20 12:31:39 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376672, encodeId=7dd113e6672a9, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Mon Mar 22 14:31:39 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1689579, encodeId=b05f16895e9cd, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu Sep 16 14:31:39 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059966, encodeId=af10205996664, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 16 22:31:39 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952228, encodeId=e62b19522288c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Nov 20 12:31:39 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376672, encodeId=7dd113e6672a9, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Mon Mar 22 14:31:39 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1689579, encodeId=b05f16895e9cd, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu Sep 16 14:31:39 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059966, encodeId=af10205996664, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 16 22:31:39 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952228, encodeId=e62b19522288c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Nov 20 12:31:39 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376672, encodeId=7dd113e6672a9, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Mon Mar 22 14:31:39 CST 2021, time=2021-03-22, status=1, ipAttribution=)]
    2021-11-20 Eleven11
  4. [GetPortalCommentsPageByObjectIdResponse(id=1689579, encodeId=b05f16895e9cd, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu Sep 16 14:31:39 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059966, encodeId=af10205996664, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Nov 16 22:31:39 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952228, encodeId=e62b19522288c, content=<a href='/topic/show?id=d62f1e60618' target=_blank style='color:#2F92EE;'>#TNM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17606, encryptionId=d62f1e60618, topicName=TNM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Nov 20 12:31:39 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376672, encodeId=7dd113e6672a9, content=<a href='/topic/show?id=c0261e607d0' target=_blank style='color:#2F92EE;'>#TNM分期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17607, encryptionId=c0261e607d0, topicName=TNM分期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb32388, createdName=linne320, createdTime=Mon Mar 22 14:31:39 CST 2021, time=2021-03-22, status=1, ipAttribution=)]

相关资讯

WCLC 2020:Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性

两种抗体药物偶联物(ADCs)对晚期NSCLC患者均具有令人鼓舞的疗效。

百济神州PD-1第6项适应症上市申请获受理,治疗非小细胞肺癌

今日,百济神州宣布,中国国家药品监督管理局(NMPA)药品审评中心(CDE)已受理其抗PD-1抗体百泽安?(替雷利珠单抗)用于治疗接受铂类化疗后出现疾病进展的二或三线局部晚期或转移性非小细胞肺癌(NS

WCLC 2020:Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期

在接受过辅助化疗的患者中,Tagrisso辅助剂可将疾病复发或死亡的风险降低84%(危险比[HR]为0.16、95%置信区间0.10-0.26)。

Eur Radiol:如何无创性准确非小细胞肺癌患者前纵隔淋巴结是否发生转移?

对于有肿瘤病史的患者,影像上评估淋巴结是否转移主要依赖于淋巴结直径大小。对此,尚无法明确诊断直径<1cm的转移性淋巴结或直径>1cm的炎性反应性淋巴结。

Nat Med:新辅助药物纳武单抗单药治疗或联合伊匹单抗治疗可进行手术的非小细胞肺癌患者的临床研究

超过50%的可进行手术治疗的转移性非小细胞肺癌(NSCLC)患者仅在手术后就会出现疾病的复发。在围手术期进行化疗(新辅助疗法或辅助疗法)仅能使患者的5年总生存期(OS)略有改善(约改善5%),且可能产

Eur Radiol:放射组学模型中CT层厚预测非小细胞肺癌生存率的影响

在临床实践中,不同机构之间用于获取图像的CT层厚度通常有所差别,用于放射组学分析的最佳CT层厚度尚未确定。